The AFP-L3% assay is intended for use in the assessment of risk for the development of hepatocellular carcinoma (HCC) in patients with chronic liver diseases.
Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy.
Gold serum separator (SST) tube
Spin and separate
Refrigerated (preferred) - 9 days
Frozen - 9 days
Ambient - 9 days
Liquid-phase Binding assay
AFP Serum: 0.0 - 8.0 ng/dL
AFP L3%: 0.0 - 9.9 %